 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | HD-CAR-1 / Heidelberg University Hospital, Gazyva (obinutuzumab) / Roche, Biogen
Journal, CAR T-Cell Therapy: CD19.CAR-T cells versus Obinutuzumab-Who will win the race on deep B cell depletion in systemic autoimmunity? (Pubmed Central) - Sep 3, 2024
No abstract available
- | HD-CAR-1 / Heidelberg University Hospital
Preclinical, Journal, CAR T-Cell Therapy: CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models. (Pubmed Central) - May 28, 2024
Collectively, our in-vitro and in-vivo data demonstrate enhanced therapeutic efficacy of CD19-CAR when combined with CD20-BsAb in B-cell malignancies. Activation and proliferation of both infused CAR T-cells as well as endogenous T-cells may contribute to improved disease control.
- HD-CAR-1 / Heidelberg University Hospital
CD19.CAR-T CELL-CONTAINING COMBINATION THERAPY IN SYSTEMIC SCLEROSIS (Poster View) - Mar 29, 2024 - Abstract #EULAR2024EULAR_2573;
Learning points for clinical practice: This case study suggests safety and unprecedented efficacy of this CAR-T combination in severe SSc-ILD. Hypothetically, disappearing circulating immune complexes and recovering Fc?R-bearing cells could contribute to the great success of CAR-T cells in systemic autoimmune diseases.
- Isocel (ALEXIS-ISO-1) / Kiromic, Yescarta (axicabtagene ciloleucel) / Gilead, HD-CAR-1 / Heidelberg University Hospital
CAR-T CELL TREATMENT OF LARGE B-CELL LYMPHOMA (LBCL): DO PROGRAM DURATION AND TREATMENT LINE MATTER? (CLYDE) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1085;
This might be partly explained with better patient selection, earlier use of CARTs, and more effective bridging strategies. The advent of 2L CARTs associates with a strong reduction, but not a complete abrogation of >2L indications.
- Isocel (ALEXIS-ISO-1) / Kiromic, Yescarta (axicabtagene ciloleucel) / Gilead, HD-CAR-1 / Heidelberg University Hospital
CAR-T CELL TREATMENT OF LARGE B-CELL LYMPHOMA (LBCL): DO PROGRAM DURATION AND TREATMENT LINE MATTER? (ePoster area) - Feb 14, 2024 - Abstract #EBMT2024EBMT_1084;
This might be partly explained with better patient selection, earlier use of CARTs, and more effective bridging strategies. The advent of 2L CARTs associates with a strong reduction, but not a complete abrogation of >2L indications.
- Tecartus (brexucabtagene autoleucel) / Gilead
A PROPENSITY SCORE-MATCHED ANALYSIS ON OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL FROM ZUMA-2 AND ALLOGENEIC STEM CELL TRANSPLANTATION FROM EBMT DATABASE IN RELAPSED/REFRACTORY POST-BTKI MANTLE CELL LYMPHOMA (Hall 2) - Feb 14, 2024 - Abstract #EBMT2024EBMT_826;
Brexu-cel is an effective treatment in patients with r/r MCL post-BTKi with a superior safety profile compared with alloSCT, as indicated by a higher one-year survival in the brexucel cohort, the lower NRM, and absence of chronic GVHD-related morbidity. Despite efforts to match patients between the cohorts, the inherent limitations of this study, such as incongruent data sources and case selection bias, have to be considered.
- | HD-CAR-1 / Heidelberg University Hospital
Journal, Combination therapy, CAR T-Cell Therapy: Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. (Pubmed Central) - Dec 23, 2023
Despite efforts to match patients between the cohorts, the inherent limitations of this study, such as incongruent data sources and case selection bias, have to be considered. No abstract available
- Opdivo (nivolumab) / Ono Pharma, BMS, HD-CAR-1 / Heidelberg University Hospital, Yervoy (ipilimumab) / Ono Pharma, BMS
The Ig Superfamily Ligand B7H6 Subjects Activated T Cells to NK Cell Surveillance and Limits CAR T Cell Persistence (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6286;
P2
We then co-injected CD19.CAR T cells and patient-autologous NK cells in leukemia-engrafted mice and observed reduced CAR T cell persistence in the peripheral blood of mice with NK cell co-injection...We therefore analyzed tissue of patients that were treated with nivolumab and ipilimumab (NCT03416244)...We therefore suggest an alternative immune checkpoint that limits T cell expansion and persistence in physiological and cellular engineering contexts. Targeting the B7H6-NKp30 axis may offer a means to modulate T cell immunity across multiple disease entities.
- Tecartus (brexucabtagene autoleucel) / Gilead
A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory ... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_4440;
Targeting the B7H6-NKp30 axis may offer a means to modulate T cell immunity across multiple disease entities. Introduction Brexucabtagene autoleucel (brexu-cel), an autologous anti-CD19 CAR T-cell therapy, is approved in the US for the treatment of relapsed/refractory (r/r) mantle cell lymphoma (MCL) and in Europe for r/r MCL after =2 prior lines of therapies, including Bruton
- HD-CAR-1 / Heidelberg University Hospital
Reshape of CAR-T cells by overexpression of TCF-1 (Y2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1488;
Downregulation of inhibitory receptors on DT-T cells may contribute to their improved performance. These findings provide insights for optimizing CAR-T cell therapy in treating B cell malignancies.
- HD-CAR-1 / Heidelberg University Hospital
3rd-Generation CD19-directed Chimeric Antigen Receptor T-Cells (CARTs) for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (X4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_755;
These findings provide insights for optimizing CAR-T cell therapy in treating B cell malignancies. Successful generation of homebrewed 3 rd generation HD-CAR-1 CARTs was possible for heavily pretreated patients with high-risk CLL and exerted a promising safety and efficacy profile.
- HD-CAR-1 / Heidelberg University Hospital
Absence of CD39 on chimeric antigen receptor (CAR) T cells is predictive for response in adult ALL patients (X4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_294;
Responses correlated with MRD clearance and were dose-dependent. Lack of CD39 expression on T cell subsets within the CART product was associated with improved anti-leukemic activity of CARTs.
- | HD-CAR-1 / Heidelberg University Hospital
Enrollment change, Trial completion date, Trial primary completion date, Viral vector: HD-CAR-1: Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR (clinicaltrials.gov) - Jun 8, 2023
P1/2, N=68, Recruiting, Sponsor: University Hospital Heidelberg
Lack of CD39 expression on T cell subsets within the CART product was associated with improved anti-leukemic activity of CARTs. N=48 --> 68 | Trial completion date: Oct 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Jan 2024
- | HD-CAR-1 / Heidelberg University Hospital
Journal, CAR T-Cell Therapy: Impact of serum?free media on the expansion and functionality of CD19.CAR T?cells. (Pubmed Central) - Jun 6, 2023
On the whole, the present study demonstrates that in general, the functionality and expansion of CAR T cells are maintained in serum?free media. Given the advantages of freedom from bovine material and consistent quality, serum?free media hold promise for the future development of the field of GMP manufacturing of CAR T?cells.
- HD-CAR-1 / Heidelberg University Hospital
THIRD-GENERATION CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS IN ADULT ALL PATIENTS (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1193;
P1/2
A specific subset of memory T cells within the CART product could predict response to treatment. Overall, HD-CAR-1 appears to be a promising step towards safe and effective ALL eradication.
- Apocept (asunercept) / Apogenix, HD-CAR-1 / Heidelberg University Hospital
BLOCKADE OF CD95/CD95L PATHWAY ENHANCES CAR T CELL PERSISTENCE AND ANTI-TUMOR EFFICACY IN VITRO AND IN VIVO (ePoster Area) - Feb 11, 2023 - Abstract #EBMT2023EBMT_1177;
CD95L blockade enhanced CAR T cell survival and promoted killing of tumor cells in vitro. Combining CAR T cell therapy with CD95L inhibitor improved CAR T cell persistence in vivo and thus enhanced the effect of CAR T cell therapy.
- HD-CAR-1 / Heidelberg University Hospital
3G.CARTs for ALL (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_75;
P1/2
In conclusion, third-generation CARTs were associated with promising clinical efficacy and remarkably low procedure-specific toxicity, thereby opening new therapeutic perspectives for patients with r/r ALL to be treated on out-patient basis. A defined biomarker expression in a specific T cell subset of the CAR T cell product predicted clinical response to CAR T cell therapy.
- HD-CAR-1 / Heidelberg University Hospital
Update on HD-CAR-1 Trial: 3 rd -generation CD19-directed CARTs for Relapsed/Refractory CLL (Poster Area) - Jan 24, 2023 - Abstract #EHAEBMTCART2023EHA_EBMT_CART_72;
P1/2
HD-CAR-1 is an investigator-initiated trial evaluating the efficacy and safety of escalating doses of CD19-directed CARTs comprising 4-1BB and CD28 as costimulatory molecules in patients with advanced B-cell malignancies after fludarabine/cyclophosphamide lymphodepletion. Successful generation of homebrewed 3rd generation HD-CAR-1 CARTs was possible for heavily pretreated patients with high-risk CLL and exerted a promising safety and efficacy profile.
- |||| HD-CAR-1 / Heidelberg University Hospital
CAR T-Cell Therapy, IO biomarker: #EBMT22 One of the five poster presentation winners: Hao Yao, Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg University, Heidelberg, Germany P079 ENHANCEMENT OF LONG-TERM FUNCTIONALITY OF CD19 CAR-T CELLS BY OVEREXPRESSION OF TCF-1 (Twitter) - Mar 25, 2022
- HD-CAR-1 / Heidelberg University Hospital
3RD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELLS (CARTS) FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – RESULTS FROM AN ACADEMIC PHASE 1/2 TRIAL (HD-CAR-1) (ePoster Area [VIRTUAL]) - Jan 30, 2022 - Abstract #EBMT2022EBMT_1184;
P1/2
HD-CAR-1 is an investigator-initiated trial evaluating efficacy and safety of escalating doses of CD19-directed CARTs comprising CD28 and 4-1BB as costimulatory molecules in patients with advanced B-cell malignancies after fludarabine/cyclophosphamide lymphodepletion. Homebrewed 3rd generation HD-CAR-1 CART could be successfully generated for heavily pretreated patients with high-risk CLL and exerted a promising safety and efficacy profile.
- HD-CAR-1 / Heidelberg University Hospital
IMPACT OF SERUM-FREE MEDIA ON THE EXPANSION AND FUNCTIONALITY OF CD19.CAR T CELLS (ePoster Area [VIRTUAL]) - Jan 30, 2022 - Abstract #EBMT2022EBMT_1009;
We could demonstrate that functionality and expansion of CARTs are maintained in serum-free media. Given the advantages of freedom from bovine material and consistent quality, serum-free media keep promise for the future development of the field of GMP manufacturing of CARTs.
- HD-CAR-1 / Heidelberg University Hospital
ENHANCEMENT OF LONG-TERM FUNCTIONALITY OF CD19 CAR-T CELLS BY OVEREXPRESSION OF TCF-1 (ePoster Area [VIRTUAL]) - Jan 30, 2022 - Abstract #EBMT2022EBMT_1007;
Given the advantages of freedom from bovine material and consistent quality, serum-free media keep promise for the future development of the field of GMP manufacturing of CARTs. Overexpression of TCF-1 might constitute a novel way to improve the functionality of CAR-T cells through the reduction of apoptosis, the improvement of proliferation, and the enhancement of the resistance to exhaustion.
- HD-CAR-1 / Heidelberg University Hospital
TREATMENT OF ADULT ALL PATIENTS WITH THIRD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS - RESULTS OF THE HEIDELBERG TRIAL 1 (HD-CAR-1 TRIAL) (Forum Hall / Virtual Hall 2) - Jan 30, 2022 - Abstract #EBMT2022EBMT_952;
P1/2
HD-CAR-1 product manufacturing was feasible for all patients enrolled in HD-CAR-1 so far. In adult patients with r/r ALL, third-generation HD-CAR-1 CAR T cells displayed an excellent safety profile as well as high clinical efficiency.
- | HD-CAR-1 / Heidelberg University Hospital
Trial completion date, Trial primary completion date, Viral vector: HD-CAR-1: Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR (clinicaltrials.gov) - Nov 20, 2020
P1/2, N=48, Recruiting, Sponsor: University Hospital Heidelberg
In adult patients with r/r ALL, third-generation HD-CAR-1 CAR T cells displayed an excellent safety profile as well as high clinical efficiency. Trial completion date: Oct 2020 --> Oct 2023 | Trial primary completion date: Mar 2020 --> Apr 2023
- | HD-CAR-1 / Heidelberg University Hospital
New P1/2 trial, Viral vector: HD-CAR-1: Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR (clinicaltrials.gov) - Sep 17, 2018
P1/2, N=48, Recruiting, Sponsor: University Hospital Heidelberg